Provided by Tiger Trade Technology Pte. Ltd.

Teva Pharmaceutical

36.44
-1.1800-3.14%
Post-market: 36.34-0.1000-0.27%19:55 EDT
Volume:3.14M
Turnover:115.07M
Market Cap:42.45B
PE:60.73
High:37.42
Open:37.37
Low:36.37
Close:37.62
52wk High:38.37
52wk Low:17.94
Shares:1.17B
Float Shares:1.09B
Volume Ratio:0.70
T/O Rate:0.29%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.6000
EPS(LYR):1.21
ROE:9.69%
ROA:5.13%
PB:5.48
PE(LYR):30.12

Loading ...

Teva announces new data on AUSTEDO tablets, AUSTEDO XR tablets

TIPRANKS
·
Jun 05

Teva launches Ahzantive in Europe

TIPRANKS
·
Jun 04

Teva Pharmaceutical Industries Rolls Out Ahzantive in Europe to Treat Retinal Diseases

MT Newswires Live
·
Jun 04

BRIEF-Teva Expands European Biosimilars Portfolio With Launch Of AHZANTIVE Biosimilar To Eylea

Reuters
·
Jun 04

Teva - Expects to Launch Ahzantive in More Markets Later in 2026

THOMSON REUTERS
·
Jun 04

Teva Expands European Biosimilars Portfolio With Launch of Ahzantive® (Aflibercept) Biosimilar to Eylea®

THOMSON REUTERS
·
Jun 04

Alvotech, Teva Resubmit 2 Proposed Biosimilar Applications to the FDA for Retinal Treatment

MT Newswires Live
·
Jun 04

Update: UroGen Settles Patent Dispute With Teva; Generic Jelmyto Delayed Until 2030

MT Newswires Live
·
Jun 02

Piper Sandler Keeps Their Buy Rating on Teva Pharmaceutical (TEVA)

TIPRANKS
·
Jun 01

Teva Shareholders Back Board, Executive Pay and Auditor

TIPRANKS
·
May 29

Analysts Offer Insights on Healthcare Companies: Teva Pharmaceutical (TEVA), Thermo Fisher (TMO) and Eli Lilly & Co (LLY)

TIPRANKS
·
May 27

Teva announces EMA acceptance of MAA for olanzapine long-acting injectable

TIPRANKS
·
May 22

Teva Study Finds Only 23% of Younger Adults With Mood Disorders and Tardive Dyskinesia (TD) Symptoms Are Formally Diagnosed With TD Despite Widespread Impact

THOMSON REUTERS
·
May 18

Teva put volume heavy and directionally bearish

TIPRANKS
·
May 15

Teva, Upstart, Bloom, Corning, Seagate Insider Shock

TIPRANKS
·
May 09

Top Teva Executives Cash Out in Major Insider Stock Moves

TIPRANKS
·
May 08

A Look At Teva Pharmaceutical Industries (NYSE:TEVA) Valuation After Strong Q1 2026 And Biopharma Pipeline Progress

Simply Wall St.
·
May 07

Teva Pharmaceuticals Is Maintained at Overweight by Barclays

Dow Jones
·
May 06

Teva Earnings Call Highlights Innovative-Driven Margin Upswing

TIPRANKS
·
May 06

Is It Too Late To Reassess Teva Pharmaceutical Industries (TEVA) After Its Strong Multi Year Rally?

Simply Wall St.
·
May 06